Avoro Capital Advisors Adds $19M in Xenon Pharmaceuticals Inc. ($XENE)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Avoro Capital Advisors increased its position in Xenon Pharmaceuticals Inc. ($XENE) by 6.51% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,777,777 shares of Xenon Pharmaceuticals Inc. after buying 353,333 shares during the quarter. Avoro Capital Advisors's holdings in Xenon Pharmaceuticals Inc. were worth $302.87 million as of its most recent filing.
Xenon Pharmaceuticals Inc. Stock Down 12.6%
Shares of Xenon Pharmaceuticals Inc. ($XENE) traded around $52.42 on Saturday, down 12.6% for the day.
Xenon Pharmaceuticals Inc. Earnings
Analysts Set New Price Targets
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Get Xenon Pharmaceuticals Inc. alerts
New 13F filings, insider trades, and analyst moves on $XENE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.